Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: CytoGam in High Risk (D+R-) Transplant Recipients
NCT06958796Phase 4Recruiting
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of IgPro10 in cytomegalovirus infection (CMV). Started Nov 2025; status: recruiting.
02
Drugs
IgPro10
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06958796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958796.